Nucleome Therapeutics, a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, has announced the appointment of Dr Michelle Morrow as Chief Scientific Officer (CSO).
Michelle joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Most recently she was CSO at Avacta Therapeutics, where she provided strategic leadership of discovery and preclinical research and led its oncology programme through candidate selection to IND approval.
Prior to this Michelle was SVP, Head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics where she held positions of increasing responsibility and most recently she was SVP, Head of Research. She also held senior scientific roles at MedImmune (now AstraZeneca).
Dr Mark Bodmer, Chief Executive Officer at Nucleome Therapeutics, said: “We warmly welcome Michelle to Nucleome. She brings a wealth of experience in advancing drug discovery candidates through the clinical pathway. Her deep expertise in immunology and bispecific antibody therapeutics will be critical as Nucleome accelerates its ambition to tackle the molecular causes of inflammatory disease.”
Michelle added: “Nucleome’s ability to access previously untapped biology creates a powerful opportunity to deliver first-in-class immunomodulatory therapies and I am eager to work with the team to advance these programmes towards the clinic and ultimately bring meaningful impact to patients’ lives.”
